J4

• 临床研究 • 上一篇    下一篇

肿瘤相关糖抗原sTn在乳腺肿瘤组织的表达

李洋1,张彬*,王兴华,崔有彬1,付彤2   

  1. 1.吉林大学第一医院胸外科,吉林 长春 130021;2.吉林大学第一医院乳腺外科,吉林 长春 130021
  • 收稿日期:2006-03-30 修回日期:1900-01-01 出版日期:2007-01-28 发布日期:2007-01-28
  • 通讯作者: 付彤

Expression of tumor-associated carbohydrate antigen sTn in breast neoplasm

LI Yang1, ZHANG Bin*, WANG Xing-hua, CUI You-bin1, FU Tong2   

  1. 1.Department of Thoracic Surgery, First Hospital, Jilin University, Changchun 130021,China;2. Department of Breast Surgery, First Hospital, Jilin University, Changchun 130021, China
  • Received:2006-03-30 Revised:1900-01-01 Online:2007-01-28 Published:2007-01-28
  • Contact: FU Tong

摘要: 目的:研究乳腺肿瘤病理标本中肿瘤相关糖抗原sTn的表达及乳腺癌组织中sTn表达与肿瘤大小、患者年龄、绝经、腋窝淋巴结转移、临床分期、病理分级和雌激素受体的关系。方法:应用单克隆抗体TKH-2(McAb TKH-2)用免疫组化方法检测sTn在46例乳腺癌、4例乳腺腺瘤和2例男性乳腺增生中的表达。应用链霉素抗生物素蛋白-过氧化酶免疫组化染色法(S-P法)检测46例乳腺癌雌激素受体(ER)水平。结果:乳腺腺瘤和男性乳腺增生患者sTn表达均呈阴性。46例乳腺癌患者中,28例sTn表达阳性(60.9%)。乳腺癌患者中sTn表达阳性频数有腋窝淋巴结转移者高于无腋窝淋巴结转移者(P<0.05 ),临床分期较晚患者高于临床分期较早患者(P<0.05 ),雌激素受体阳性者高于雌激素受体阴性者(P<0.05)。在病理分级、年龄、是否绝经、肿瘤直径大小患者中的sTn表达阳性频数分布差异无显著性(P>0.05 )。46例乳腺癌患者中,25例雌激素受体阳性(54.3%)。结论:乳腺癌中sTn表达阳性患者易发生在腋窝淋巴结转移、临床分期较晚且雌激素受体阳性率升高患者,sTn可以作为判定乳腺癌预后的指标,sTn和雌激素受体联合检测对判断乳腺癌预后意义更大。

关键词: 遗传学, 肿瘤标记, 生物学, 糖抗原, 受体, 雌激素

Abstract: Abstract:ObjectiveTo investigate the expression of tumor-associated carbohydrate antigen sTn in breast neoplasm, and analyzed the association between the expression of sTn and size of tumor, age, menopause, axillary lymph node metastasis, clinical stage, pathologic grade and the level of estrogen receptor in breast carcinoma. MethodsThe monoclonal antibody TKH-2 was used to detect the immunohistochemical expression of sTn in 46 cases of breast carcinoma, 4 breast adenoma and 2 gynecomastia. The level of estrogen receptor was detected by S-P method in 46 breast carcinoma. ResultsImmunohistochemical expression of sTn was not detected in breast adenoma and gynecomastia. The expression of sTn was found in 28 of 46 breast carcinoma (60.9%). The expression of sTn was significantly associated with axillary lymph node metastasis (P<0.05), clinical stage (P<0.05) and the level of estrogen receptor (P<0.05) in breast carcinoma. But there was no apparent relationship between the expression of sTn and size of tumor(≥2cm), age, menopause and pathologic grade (P>0.05). In 46 breast carcinoma, the positive quantity of estrogen receptor was 25 (54.3%). ConclusionSTn immunostaining appears to be a poor prognostic factor in patients with breast carcinoma. It is more useful in detecting the expression of sTn together with the level of estrogen receptor in breast carcinoma to investigate the prognosis of the patients.

Key words: genetics, tumor markers, biological, carbohydrate antigens, receptors, estrogen

中图分类号: 

  • R737.9